Publications by authors named "Elizabeth Troll"
Article Synopsis
- The study compared stage III inflammatory breast cancer patients who underwent either 1 or 2-3 lines of neoadjuvant chemotherapy before surgery, focusing on their pathologic complete response (pCR), breast cancer-free survival (BCFS), and overall survival (OS).
- Out of 808 patients analyzed, 91% received the first line of chemotherapy, with lower pCR rates and poorer BCFS observed in those requiring additional lines, although pCR rates showed no significant difference between the two groups.
- The findings suggest that while patients needing more chemotherapy before surgery had worse BCFS and OS rates overall, those with pCR had similar outcomes regardless of the number of chemotherapy lines.
Background: Prophylactic lymphatic bypass or LYMPHA (LYmphatic Microsurgical Preventive Healing Approach) is increasingly offered to prevent lymphedema following breast cancer treatment, which develops in up to 47% of patients. Previous studies focused on intraoperative and postoperative lymphedema risk factors, which are often unknown preoperatively when the decision to perform LYMPHA is made. This study aims to identify preoperative lymphedema risk factors in the high-risk inflammatory breast cancer (IBC) population.
View Article and Find Full Text PDFInflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer that presents as de novo metastatic disease in 20-30% of cases, with one-third of cases demonstrating HER2-positivity. There has been limited investigation into locoregional therapy utilization following HER2-directed systemic therapy for these patients, and their locoregional progression or recurrence (LRPR) and survival outcomes. Patients with de novo HER2-positive metastatic IBC (mIBC) were identified from an IRB-approved IBC registry at Dana-Farber Cancer Institute.
View Article and Find Full Text PDF